Smith & Nephew SNATS

Smith & Nephew SNATS FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Smith & Nephew SNATS (SNN) as of Nov 3, 2026 is 136.32 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 147.09 % — a change of -7.32% (lower).

FCF Conversion

136.32 %

YoY

-7.32%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Smith & Nephew SNATS is 2025 136.32 % . FCF Conversion Rate (FCF/EBITDA) of Smith & Nephew SNATS was 2024 147.09 % . It decreases by -7.32% lower compared to the previous year.

The Smith & Nephew SNATS FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
88.08 USD
Jan 1, 2019
126.67 USD
Jan 1, 2020
109.82 USD
Jan 1, 2021
89.50 USD
Jan 1, 2022
49.33 USD
Jan 1, 2023
68.82 USD
Jan 1, 2024
147.09 USD
Jan 1, 2025
136.32 USD
The Smith & Nephew SNATS FCF Conversion history
YEARFCF ConversionYoY
136.32 %-7.32%
147.09 %+113.72%
68.82 %+39.52%
49.33 %-44.89%
89.50 %-18.50%
109.82 %-13.30%
126.67 %+43.80%
88.08 %-5.38%
93.09 %+37.96%
67.47 %-61.95%
177.32 %+130.74%
76.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Smith & Nephew SNATS Stock analysis

What does Smith & Nephew SNATS do? Smith & Nephew SNATS Inc operates in the medical device sector, focusing on orthopaedic implants and surgical solutions. The company generates revenue through knee and hip implant products used in joint replacement procedures, including revision surgeries. Its trauma and extremities segment offers internal and external devices for fracture stabilization and deformity correction. Sports Medicine & ENT segment sells joint repair products, arthroscopic equipment, and tissue resection devices for minimally invasive surgeries. Advanced Wound Management provides specialized wound care solutions, though specific products are not detailed in the description. The primary buyers are healthcare providers and hospitals globally, particularly in the United Kingdom, United States, and international markets. Orthopaedics and Sports Medicine & ENT segments target surgeons and orthopaedic specialists, while Advanced Wound Management serves wound care professionals. The company’s products are sold under its own brand, with no external brand names mentioned in the description. Revenue streams include direct sales of medical devices to hospitals and clinics, with no mention of subscription models or service-based fees. The company’s focus on surgical solutions and implants drives its market position, with key segments defined by product categories rather than geographic regions. No additional revenue streams like data services or digital platforms are referenced in the business description. Smith & Nephew SNATS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Smith & Nephew SNATS stock

FCF Conversion Rate (FCF/EBITDA) of Smith & Nephew SNATS is 136.32 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Smith & Nephew SNATS changed from 147.09 % to 136.32 %, representing a -7.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Smith & Nephew SNATS since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Smith & Nephew SNATS with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Smith & Nephew SNATS

All Key Metrics — Smith & Nephew SNATS